Luigi Meneghini, M.D.
Professor

Luigi Meneghini, MD, MBA is a Professor of Internal Medicine at the University of Texas Southwestern Medical Center, Division of Endocrinology, in Dallas, Texas, and Executive Director of the Parkland Health and Hospital System Global Diabetes Program. He recently joined UT Southwestern after a 20-year tenure at the University of Miami Miller School of Medicine where he was Professor of Clinical Medicine and Director of the Kosow Diabetes Treatment Center.

Dr. Meneghini’s primary interests lie in improving the lives of patients with diabetes through the application of cutting edge therapies and technologies, and the implementation of these treatment strategies through patient and professional education activities. He has been involved in the development of treatment algorithms for glycemic control of type 1 and type 2 diabetes. At UT Southwestern he is charged with implementing a registry based chronic care model and exploring opportunities for leveraging this infrastructure to optimize population-based health management and translational research.

Dr. Meneghini is a frequent lecturer and has published numerous articles in peer-reviewed medical journals. He has presented numerous projects at the Scientific Sessions of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). He is a native of Italy and speaks Italian, French, English, and Spanish fluently. While he thoroughly enjoys a good laugh, especially over a good meal and bottle of wine, the greatest love of his life is his wife and family.

Medical School

Emory University School of Medicine (1988)

Internship

Jackson Memorial Hospital (1991), Internal Medicine

Fellowship

Jackson Memorial Hospital (1993), Endocrinology & Metabolism

• Impact of education on diabetes self-management
• Insulin replacement for glycemic control
• Use of technologies for glycemic control

Featured Publications

Barriers to Initiating Insulin in Type 2 Diabetes Patients: Development of a New Patient Education Tool to Address Myths, Misconceptions and Clinical Realities.

Brod M, Alolga SL, Meneghini L Patient 2014 Jun

Insulin stacking versus therapeutic accumulation: understanding the differences.

Heise T, Meneghini LF Endocr Pract 2014 Jan-Feb 20 1 75-83

Intensifying insulin therapy: what options are available to patients with type 2 diabetes?

Meneghini LF Am. J. Med. 2013 Sep 126 9 Suppl 1 S28-37

Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.

Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P Diabetes Obes Metab 2013 Aug 15 8 729-36

Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice.

Umpierrez GE, Meneghini L Endocr Pract 2013 Jul-Aug 19 4 718-28

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.

Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begtrup K, Birkeland KI Diabetes Care 2013 Apr 36 4 858-64

Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.

Freemantle N, Meneghini L, Christensen T, Wolden ML, Jendle J, Ratner R Diabet. Med. 2013 Feb 30 2 226-32

The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.

Khunti K, Caputo S, Damci T, Dzida GJ, Ji Q, Kaiser M, Karnieli E, Liebl A, Ligthelm RJ, Nazeri A, Orozco-Beltran D, Pan C, Ross SA, Svendsen AL, Vora J, Yale JF, Meneghini LF Diabetes Obes Metab 2012 Jul

Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study.

Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K Endocr Pract 2011 Sep-Oct 17 5 727-36

Early insulin treatment in type 2 diabetes: what are the pros?

Meneghini LF Diabetes Care 2009 Nov 32 Suppl 2 S266-9

 Featured Books

Pathophysiology of Type 1 Diabetes. In Type 1 Diabetes in Adults: Principles and Practices

Meneghini LF (2008). New York, NY, Informa Healthcare USA

• American Association of Clinical Endocrinologists (2013)
• American Diabetes Association (2013)
• Dallas County Medical Society (2013)
• Endocrine Society (2013)
• Texas Medical Association (2013)